NEW YORK (GenomeWeb News) — Illumina has made several management changes in the wake of its acquisition of Solexa last month. John West, the former CEO of Solexa, has joined Illumina as senior vice president and general manager of the sequencing business; John Stuelpnagel, Illumina’s COO, will now also serve as general manager of the company’s microarray business; Tristan Orpin, Illumina’s vice president of sales, has been promoted to senior vice president in charge of all commercial operations; Christian Henry, vice president and CFO, has been promoted to senior vice president and CFO and has assumed the additional responsibility of investor relations; Matt Posard, vice president of marketing, is now vice president of sales; while Omead Ostadan, formerly vice president of marketing at Solexa, will replace Posard as vice president of marketing at Illumina. In addition, Solexa directors Blaine Bowman and Roy Whitfield have joined Illumina’s board.
Gen-Probe has hired Carl Hull as executive vice president and COO, the company said this week.
Hull recently was at Applied Biosystems, where he served as vice president and general manager of the company’s Sequence Detection System and microarray business unit.
Hull also was a CEO at Applied Imaging and he worked in marketing and sales at Ventana Medical Systems and at Abbott Laboratories.
Former Affymetrix CFO Gregory Schiffman has joined the board of directors of Entelos, the company said this week. Schiffman is CFO at Dendreon. He also was a vice president and controller for Applied Biosystems and a manager at Hewlett Packard and at IBM.
Institute for Systems Biology co-founder Lee Hood will be inducted into the National Inventors Hall of Fame, the Institute said last week.
He is being honored for helping to develop the DNA-sequencing technology that was used in the Human Genome Project.
An awards ceremony featuring Hood and several other inventors will be held May 4-5 in Akron, Ohio. The NIHF annually awards individuals with patented inventions that may be of benefit to society.
Biowisdom has appointed Jack Reynolds as chairman of the board of its safety intelligence program, the company said this week.
He will act as a scientific advisor and will work on the development and implementation of the safety intelligence program.
Reynolds formerly worked at Pfizer as senior vice president of R&D and head of safety sciences and comparative medicine, Biowisdom said.
Tecan this week said it will nominate Heinrich Fisher to the company’s board of directors at a shareholders meeting on April 17.
Fisher will step down from his position as CEO of Saurer in April, and Tecan said he has made known his willingness to be nominated for the board.
Mendel Biotechnology has named Neal Gutterson president and CEO, the company said this week.
Neal has served as president and COO since 2005.
Compendia Bioscience said this week it has filled in its entrepreneurial management team, which includes company co-founder and CSO Dan Rhodes.
Compendia CEO John Freshley formed a group including David Denny as director of product management, Peter Wyngaard as vice president of product development, Matt Anstett as vice president of scientific applications, and Colleen Kincaid-Beal as director of operations.
The North Carolina Biotechnology Center said this week it is seeking a new president to take over for Leslie Alexandre, who resigned after serving as president and CEO for four years.
The non-profit that promotes biotech business and education in North Carolina said it has appointed a nine-member search committee and said current senior vice presidents Ken Tindall, Steven Burke, and Lori Greenstein will manage the organization until Alexandre’s replacement is found.
ThermoGenesis this week said it has named Daniel Segal to the post of vice president of sales and marketing for its cell therapy unit.
Segal recently worked at GE Healthcare as a business development manager.
Segal was at ThermoGenesis before, between 1997 and 2004, when he served in sales and marketing for the company’s BioArchive products.
Epitome Biosystems has named Jeffrey Radding vice president of research and development, the company said this week.
Radding was formerly with Eli Lilly, where he was involved in cell signaling approaches with the platform biology group.